Updates on Combination Therapy for Lung Cancer vol. II

  • 3,014

    Total downloads

  • 11k

    Total views and downloads

About this Research Topic

Submission closed

Background

Lung cancer is a leading cause of death worldwide, accounting for nearly 1.80 million deaths in 2020. It is the most common cancer in both sexes with 2.21 million new cases diagnosed in 2020. Nevertheless, in the past few years, most Western countries have recorded a decline in lung cancer morbidity and mortality according to the American Cancer Society. This achievement is largely due to the institution of enhanced strategies for the prevention, screening, early diagnosis, and treatment of same. In contrast, lung cancer incidence is still increasing in most low- and middle-income countries, due to a lack of access to early diagnosis and treatment. Comprehensive treatment is reportedly available in more than 90% of high-income countries but less than 15% in low-income countries.

Lung cancer is made up of a group of molecularly and histologically heterogeneous subtypes, which are classified as either non-small cell lung cancer (NSCLC; 85%) or small cell lung cancer (SCLC; 10-15%). Appropriate treatment is based on whether the tumor is NSCLC or SCLC, as well as its stage and molecular characteristics. Despite the advancement in treatment, lung cancer still has a poor prognosis and the lowest 5-year survival rate as compared to the other cancer sites. Multiple factors are responsible for this, including cigarette smoking, sociodemographic factors, abnormal progression of the disease such as metastasis, and resistance to currently available anticancer therapies. For instance, 80% of lung cancer deaths in the United States are still caused by cigarette smoking. Moreover, most patients in underserved communities are diagnosed at an advanced stage after the initiation of metastasis. These geographic disparities in disease occurrence will probably worsen the overall survival rate of lung cancer patients.



The problem of drug resistance caused by single-drug chemotherapy has increased in recent years. By comparison, combination therapy, the use of more than one type of therapy in treating a patient, is a hallmark of cancer treatment. However, multiple drugs may increase the risk of drug interactions. To address this potential risk and elevate the likelihood treatment will be effective, chemotherapy is sometimes used along with immunotherapy, immunotherapy with anti-vascular targeting, immunotherapy with radiotherapy, immunotherapy with immunotherapy, etc.



Since chemotherapy drugs affect cancer cells at different points in the cell cycle, using a combination of drugs increases the chance that all of the cancer cells will be eliminated.



The complexity of the disease – its tendency to spread beyond its original site and become resistant to certain drugs, and its genetic diversity – underscores the need for a variety of approaches to attack it. In many cases, combination therapy not only increases the chances of a cure or long-term remission but also reduces damage to vital organs and tissues more than a single approach.



This Research Topic aims to review the current state-of-the-art strategies in lung cancer therapy and provide updates on the combination therapy. This topic, therefore, covers cutting-edge research, review articles, editorials, and correspondence from experts in the field of clinical, translational, and basic science in lung malignancies including but not limited to the following topics:



• Combination therapies

• Combination chemotherapy

• Antiangiogenic therapy

• Chemo-immunotherapy

• Immune checkpoint inhibitors

• Chemoradiotherapy

• Targeted therapy

• New Lung cancer treatment

Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Keywords: lung cancer, Non-small cell lung cancer, Small cell lung cancer, Prognostic factors, Combination therapies, Checkpoint inhibitors, Chemotherapy, Immunotherapy, Targeted therapy, Radiotherapy, Survival outcomes, Novel therapies

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Frequently asked questions

  • Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

    Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

  • The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

    Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

  • As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

    A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

  • Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

    In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

  • Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

    As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

    Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

  • Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

    Check available article types here 

  • Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

    Suggest your topic here 

  • A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

    The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

  • As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

    You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

  • As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

  • If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

  • Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

  • Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

  • As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

    Find out more about our Research Topics

  • Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

    Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

  • In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.

Participating Journals

Impact

  • 11kTopic views
  • 7,819Article views
  • 3,014Article downloads
View impact